|
|
| | LY2157299 Basic information |
| Product Name: | LY2157299 | | Synonyms: | Galunisertib Hydrate;4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide,hydrate;LY2157299 (hydrate);Galunisertib Monohydrate | | CAS: | 924898-09-9 | | MF: | C22H21N5O2 | | MW: | 387.44 | | EINECS: | | | Product Categories: | | | Mol File: | 924898-09-9.mol |  |
| | LY2157299 Chemical Properties |
| | LY2157299 Usage And Synthesis |
| Uses | Galunisertib monohydrate is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM. | | References | [1] Bueno L, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008 Jan;44(1):142-50. DOI:10.1016/j.ejca.2007.10.008
[2] Cong L, et al. Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy. Arch Pharm (Weinheim). 2014 Sep;347(9):609-15. DOI:10.1002/ardp.201400116
[3] Serova M, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget. 2015 Aug 28;6(25):21614-27 DOI:10.18632/oncotarget.4308
[4] Herbertz S, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015 Aug 10;9:4479-99. DOI:10.2147/DDDT.S86621 |
| | LY2157299 Preparation Products And Raw materials |
|